Prolactinoma
Conditions
Interventions
Drug-resistant group:None
Sponsors
Huashan Hospital Fudan University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: a.Patients diagnosed with prolactinoma under either bromocriptine or cabergoline treatment for at least 6 months were recruited. b.Age: 18-70 years old. c.Treated with bromocriptine or cabergoline for at least half a year. d.Resistance group (case group): After taking bromocriptine >=15 mg/day or cabergoline >=2 mg/week for at least 3 months, the prolactin level does not drop to normal or the tumor volume does not shrink by 50%. Sensitive group (control group): Prolactin levels decreased to normal or tumor volume decreased by >50% after taking bromocriptine or cabergoline
Exclusion criteria
Exclusion criteria: a)Hyperprolactinemia caused by other causes: such as drug-induced, physiological, pituitary stalk blockade effect, etc b)Treatment with other types of dopamine agonists c)Received radiation therapy d)Women who are pregnant, lactating, or have a need for pregnancy in the last 3 months e)Participating in other clinical studies f)Combined with other systemic diseases such as heart disease, liver and kidney insufficiency, psychiatric diseases, etc., or the investigator considers it unsuitable to participate in clinical trials g)Claustrophobia or inability to undergo an MRI
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| T2 value; | — |
Secondary
| Measure | Time frame |
|---|---|
| SI ratio; | — |
Countries
China
Contacts
Public ContactLijin Ji
Huashan Hospital Fudan University
Outcome results
None listed